Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In this video, Jeff Yu, MD, MS, emphasized the importance of chronic hand eczema awareness and highlighted a study on the causes and treatments of the disease, presented at the Revolutionizing Atopic ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

Any physical activity can be beneficial for eczema, as long as you’re choosing the right clothing and practicing good habits ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Discover a study that links air pollution and climate extremes to increased severity and prevalence of atopic dermatitis.